Autopsy report · NCT04471415
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
Cause of deathFunding or business
“Company decision to closing study and discontinue further patient enrollment.”
Life of this trial
- Registered 2 months before it started.
- Ran for about 2 years 7 months before it stopped.
- 61 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Dracen Pharmaceuticals, Inc.
- Sponsor type
- Industry
- Conditions
- Advanced Solid Tumor; Non Small Cell Lung Cancer Metastatic
- Interventions
- DRP-104; atezolizumab
- Participants
- 61
- Sites
- 22
- Countries
- Germany, Singapore, Spain, Taiwan, United States
Trials that died the same way
- Adipose Derived SVF for Aero-digestive & Enterocutaneous Fistulae
“Study closed due to lack of patient enrollment.” - The Metabolomics of Anaphylaxis
“We are closing the study because of lack of enrollment.” - Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
“Study closed before patients enrolled” - Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
“This study was closed to enrollment as of 13 May 2011 due to business reasons. Premature closure was not prompted by any safety or efficacy concerns.” - Reiki for the Management of Neuropathic Pain
“Study closed due to substantial decrease in the desired patient population.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.